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Background: The incidence and severity of gastroesophageal reflux disease (GERD) in Japan tends to increase in
elderly women. Rikkunshito (RKT), a traditional Japanese medicine, acts as a prokinetic agent and improves gastric
emptying and gastric accommodation. Our previous prospective randomized placebo-controlled study showed
that RKT combined with a standard-dose of rabeprazole (RPZ) significantly improved the acid-related dysmotility
symptoms (ARD) in elderly patients with proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD).
This study aimed to evaluate clinical characteristics of elderly PPI-refractory NERD patients with ARD symptoms who
responded to RKT.
Methods: Two hundred forty-two patients with PPI-refractory NERD were randomly assigned to 8 weeks of either RPZ
(10 mg/q.d.) + RKT (7.5 g/t.i.d.) (RKT group) or RPZ + placebo (PL group). Among them, 95 were elderly (≥65 years) with
ARD (RKT group: n = 52; PL group: n = 43). We analyzed the changes using the 12 subscale score of frequency
scale for the symptoms of GERD (FSSG) and 15 items of the Gastrointestinal Symptom Rating Scale at 4 and
8 weeks and compared the therapeutic efficacy between the 2 groups.
Results: There were no marked differences in baseline demographic or clinical characteristics in the 2 groups
except for rate of current smoking. The FSSG score (mean ± SD at 0, 4, and 8 weeks) in both the RKT (16.0 ± 7.0;
9.9 ± 8.4; 7.0 ± 6.4) and PL (15.1 ± 6.4; 10.9 ± 6.7, 11.1 ± 8.5) groups significantly decreased after treatment.
However, the degree of improvement of total and ARD scores of FSSG after the 8-week treatment was significantly
greater in the RKT group than in the PL group. Combination therapy with RKT for 8 weeks showed significant
improvement in 3 subscale scores (abdominal bloating, heavy feeling in stomach and sick feeling after meals) of
the ARD domain and 1 subscale score (heartburn after meals) of the reflux symptom domain.
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Conclusions: RKT may be useful for improving GERD symptoms in elderly PPI-refractory NERD patients with ARD.
Thus, RKT was particularly effective for resolving postprandial GERD symptoms (heavy feeling in stomach, sick
feeling, and heartburn after meals).
Trial registration: (UMIN000005880)
Keywords: Gastroesophageal reflux, Acid-related dysmotility, Postprandial, Herbal medicine, Elderly patientBackground
Gastroesophageal reflux disease (GERD) is a common
disorder caused by the reflux of gastric contents into the
esophagus [1]. A major therapeutic strategy for GERD is
the inhibition of acid secretion using proton pump in-
hibitors (PPIs) [2]. However, in clinical practice trouble-
some GERD symptoms persist in 20%–30% of patients
despite daily treatment with a standard PPI dose [3]. In
particular, the PPI resistance rate (40%–50%) in patients
without erosion of the esophageal mucosa [non-erosive
reflux disease (NERD)] was higher than that in patients
with reflux esophagitis (RE) [4]. Although GERD occurs
frequently in Western countries, recent epidemiological
studies suggest that the incidence of the disease is in-
creasing in Asian populations [5,6]. Elderly patients are
at risk for more severe complications from GERD, and
their relative discomfort from the disease is often less
than that from comparable pathology for younger pa-
tients [7]. One of the features of GERD in Japan is that
its frequency and severity tend to increase in elderly
women [8]. Previous studies have suggested that risk fac-
tors for esophagitis in elderly Japanese women are lum-
bar kyphosis, short height, hiatus hernia, and negative
Helicobacter pylori infection status [9,10]. In addition,
typical GERD symptoms were frequently observed in
elderly patients with GERD at the typical postprandial
times in a day, regardless of the presence of esophageal
mucosal breaks [11].
In Japan, the traditional medication rikkunshito (RKT),
in the form of extracted granules for ethical use (product
number TJ-43; Tsumura & CO., Tokyo, Japan) has been
approved for medicinal use by the Japanese Ministry of
Health and Welfare and is widely prescribed for patients
with upper gastrointestinal (GI) symptoms [12]. RKT
acts as a prokinetic agent and improves gastric emptying
[13] and gastric accommodation [14]. The GERD 4 study
revealed that RKT combined with standard-dose rabe-
prazole (RPZ) decreased the frequency scale for the
symptoms of GERD (FSSG) score in patients with PPI-
refractory GERD, similar to the decrease observed with
treatment with a double dose of RPZ in a randomized,
parallel comparative study [15]. Our previous prospect-
ive randomized multicenter placebo-controlled study,
the G-PRIDE study, showed that RKT may be useful for
improving mental quality of life (QOL) and dyspepticsymptoms in patients with PPI-refractory NERD, par-
ticularly for elderly and female patients [16]. The aim of
this study was to evaluate clinical characteristics of eld-
erly patients with PPI-refractory NERD who responded
to RKT from the G-PRIDE study.
Methods
Study design and patients
The G-PRIDE study (UMIN000005880) was a prospect-
ive, multi-center, randomized, double-blind, paralleled
comparative study that examined the pharmacological
effects, efficacy, and safety of drug therapy in patients
with PPI-refractory NERD in 55 hospitals in Japan. The
design and primary results of the prospective clinical
trial have been previously described elsewhere [16]. This
report includes prospectively defined subgroup analyses
of clinical characteristics of elderly patients with PPI-
refractory NERD from the G-PRIDE study who responded
to RKT. Briefly, 242 patients with PPI-refractory NERD
were enrolled in this study from April 2011 to July 2012.
Patients with PPI-refractory NERD were defined as those
without endoscopic mucosal breaks and with GERD
symptoms (FSSG score ≥8) despite a prior therapy with a
standard PPI dose (RPZ: 10 mg/day, omeprazole: 20 mg/
day, or lansoprazole: 30 mg/day) for ≥4 weeks. PPI-
refractory NERD met the following selection criteria: (1)
were >20 years of age; (2) had received standard-dose PPI
therapy for ≥4 weeks before the start of this study for the
treatment of NERD; (3) had an FSSG score ≥8 after
standard-dose PPI therapy for ≥4 weeks; (4) planned to re-
ceive RPZ (10 mg/day) treatment for ≥8 weeks; and (5)
provided written informed consent regarding study par-
ticipation. Exclusion criteria were as follows: (1) esopha-
geal mucosal erosion in endoscopy carried out within
6 months before the registration; (2) presence of serious
complications (liver, kidney, heart, blood, or metabolic dis-
orders); (3) having undergone resection of the upper di-
gestive tract; (4) confirmed presence of a peptic ulcer
(excluding ulcer scar) or malignant tumor of the upper di-
gestive tract; (5) inflammatory bowel disease, irritable
bowel syndrome (IBS), esophageal stenosis, or esophageal
achalasia; (6) diagnosis of a GI motility disorder by the
study investigator; (7) suspected organic hepatic/biliary/
pancreatic disorders such as gallstone, hepatitis, and pan-
creatitis; (8) hemorrhage of the digestive tract, mechanical
Table 1 Twelve questions of the FSSG questionnaire
Questions ARD/RS
1 Do you get heartburn? RS
2 Does your stomach get bloated? ARD
3 Does your stomach ever feel heavy after meal? ARD
4 Do you sometimes subconsciously rub your
chest with your hand?
RS
5 Do you ever feel sick after meals? ARD
6 Do you get heartburn after meals? RS
7 Do you have an unusual (e.g., burning) sensation
in your throat?
RS
8 Do you feel full while eating meals? ARD
9 Do some things get stuck when you swallow? RS
10 Do you get bitter liquid (acid) coming up into
your throat?
RS
11 Do you burp a lot? ARD
12 Do you get heartburn if you bend over? RS
RS, reflux symptom; ARD, acid-related dysmotility symptom.
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prohibited for concomitant use (such as anti-ulcer drugs
except for rabeprazole, prokinetics, other kampo medi-
cines except for RKT) during the observation period; (10)
psychoneurosis; (11) receiving or scheduled to receive an
agent that is being developed; (12) lactation, pregnancy, or
planned pregnancy during the study or follow-up period;
(13) intolerance to oral administration; (14) history of
allergy for kampo medicine; and (15) considered ineligible
to participate by the chief investigator. Patients were
randomized to receive RPZ (10 mg once daily) + RKT
(7.5 g/day 3 times) (RKT group) or RPZ (10 mg once
daily) + placebo (7.5 g/day 3 times) (PL group) for 8 weeks
according to a computer-generated randomization list
provided by a statistician from the site management
organization (SMO) (Sogo Rinsho Holdings Co., Ltd,
Tokyo, Japan). After written informed consent was ob-
tained from the study participants, the patients with PPI-
refractory NERD who met the inclusion criteria and did
not meet the exclusion criteria were recruited for this
study. Patients were randomly assigned to the RKT group
[RPZ (10 mg/day) + RKT (7.5 g/t.i.d.) for 8 weeks] or the
PL group (RPZ + placebo for 8 weeks). RKT (Tsumura &
Co., Tokyo, Japan) was used in the form of a powdered
extract obtained by spray drying a hot water extract mix-
ture of the following 8 crude herbs: Atractylodis lanceae
rhizoma (4.0 g), Ginseng radix (4.0 g), Pinellia tuber (4.0 g),
Hoelen (4.0 g), Zizyphi fructus (2.0 g), Aurantii nobilis
pericarpium (2.0 g), Glycyrrhizae radix (1.0 g), and
Zingiberis rhizoma (0.5 g). The fingerprint pattern pro-
vided by 3-dimensional high-performance liquid chro-
matography revealed that RKT contains several low
molecular compounds (i.e., hesperidin, liquiritin, liquir-
itigenin, isoliquilitin, isoliquiritigenin, formononetin,
glycycoumarin, glycyrrhizin, atractylodin, atractylodi-
nol, 6-shogaol, and 6-gingerol) [17]. Before and after
the 4-week and 8-week treatments, GERD symptoms
were evaluated using the FSSG questionnaire and GI-
related QOL were evaluated using the Gastrointestinal
Symptom Rating Scale (GSRS) questionnaire, similar to
what was used in earlier clinical reports [18-20]. The
study was performed in accordance with the ethical
guidelines for clinical studies and considered the patients’
rights and privacy. The study protocol was approved
by the institutional review board of each institution
(Additional file 1).
Questionnaire
The FSSG questionnaire comprised 12 items: 2 domains,
the reflux symptom (RS) domain, in which the sums of
the respective scores of items 1, 4, 6, 7, 9, 10, and 12 are
calculated; and the acid-related dysmotility symptom
(ARD) domain, in which the sums of the respective
scores of items 2, 3, 5, 8, and 11 are calculated (Table 1).The scores were calculated according to the frequency
of the symptoms as follows: never, 0; occasionally, 1;
sometimes, 2; often, 3; and always, 4 as previously re-
ported. The total score is the sum of the RS and ARD
scores, and total scores ≥8 indicated probable GERD as
previously validated [19].
The GSRS questionnaire is an inquiry table consisting of
15 items for the evaluation of general GI symptoms [20].
Each GSRS item is rated on a 7-point Likert scale from no
discomfort to very severe discomfort. Based on a factor
analysis, the 15 GSRS items break down into the following
5 scales: abdominal pain (abdominal pain, hunger pain, and
nausea), reflux syndrome (heartburn and acid regurgita-
tion), diarrhea syndrome (diarrhea, loose stools, and urgent
need for defecation), indigestion syndrome (borborygmus,
abdominal distension, eructation, and increased flatus), and
constipation syndrome (constipation, hard stools, and a
feeling of incomplete evacuation).
Clinical characteristics of elderly patients with PPI-refractory
NERD who responded to RKT
Subgroup analysis was pre-planned to perform with re-
spect to each subject’s background factors such as age
(≥65 years or ≤64 years), gender (male or female), body
mass index (BMI ≥22 or <22), classification as ARD and
RS scores of the FSSG. The patients aged ≥65 years with
ARD symptoms were selected from the patients with
PPI-refractory NERD. A patient who had one or more
ARD symptom score of FSSG was defined as a patient
with ARD symptoms. Clinical characteristics of elderly
patients with PPI-refractory NERD who responded to RKT
were assessed by improvement degrees of 12 subscale
scores of FSSG and 15 GSRS items after the treatment.
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FSSG or GSRS score before and after treatment, using
the following mentioned formula. To compare the ef-
fects between the 2 groups, the mean improvement de-
gree was used: (FSSG and GSRS) improvement degree
(Δ) = [pre scores] − [post scores]. In addition, rikkunshito
responder was defined as those whom the FSSG score
has improved 50% or more after the 8-week treatment
of RKT, and the differences in clinical characteristics be-
tween the RKT responsive group and nonresponsive
group were investigated.
Statistical analysis
The efficacy analysis was based on the full analysis set
(FAS) population. The treatment response in each group
was evaluated based on changes in the FSSG and GSRS
questionnaire scores before and after treatment, using
Wilcoxon’s signed rank test. We employed the t-test
to compare background factors such as age and BMI.
The distributions of gender, current alcohol use, current
smoking status, H. pylori infection, gastric mucosal atro-
phy, gastric mucosa redness, impaired gastroesophageal
flap valve (GEFV), and esophageal hiatal hernia (grades
B and A) were compared using Fisher’s exact test. Values
of P < 0.05 were considered statistically significant. All
data are expressed as mean ± standard deviation (S.D.).
Results
Eligible patients
Two hundred forty-two patients were randomly assigned
to the RKT group (n = 125) or the PL group (n = 117).
Twenty-five patients were excluded from the efficacy as-
sessment because they withdrew from the study after
registration (RKT group: n = 109, PL group: n = 108). Of
the 217 patients, 95 were elderly patients (≥65 years) with
ARD (RKT group: n = 52; PL group: n = 43) (Figure 1).
Background of elderly PPI-refractory NERD patients with ARD
There were no marked differences in baseline demo-
graphic or clinical characteristics in the 2 groups except
for rate of current smoking. Furthermore, there was no
difference in total FSSG or overall GSRS scores before
the start of treatment between the 2 groups (Table 2).
Changes in FSSG scores after treatments
Changes in total, ARD, and RS scores of FSSG after treat-
ments in each group are shown in Figure 2A. In both
groups, total, ARD, and RS scores of FSSG were signifi-
cantly decreased after the 4-week treatment compared
with that before treatment (P < 0.01). Total, ARD, and RS
scores of FSSG in the RKT group but not in the PL
group further decreased during 4–8 weeks after treat-
ment. Improvement degrees of total, ARD, and RS
scores of FSSG after treatments in each group areshown in Figure 2B. The improvement degrees of the
total and ARD scores but not RS score of FSSG were
significantly higher in the RKT group than in the PL
group after the 8-week treatment.
Improvement degrees of 12 subscale scores of FSSG after
the 8-week treatment
Out of 5 subscale scores of ARD, improvement degrees
of FSSG-02 (abdominal bloating), FSSG-03 (heavy feel-
ing in stomach after meals), and FSSG-05 (sick feeling
after meals) scores were significantly higher in the RKT
group than in the PL group (Figure 3A). Out of 7 sub-
scale scores of RS, improvement degree of FSSG-06
(heartburn after meals) score was significantly higher in
the RKT group than in the PL group (Figure 3B). Im-
provement degree of FSSG-12 (heartburn when bending
over) score tended to be higher in the RKT group than
in the PL group (P = 0.054, Figure 3B).
Improvement degrees of GSRS scores after the 8-week
treatment
Improvement degrees of GSRS scores after the 8-week
treatment in each group are presented in Table 3. Im-
provement degrees of reflex syndrome score of GSRS
tended to be higher in the RKT group than in the PL
group (P = 0.064). However, there was no significant dif-
ference in the degree of improvement of the overall and
5 subscale scores of GSRS between the 2 groups after
the 8-week treatment. Of the 15 GSRS items, improve-
ment degrees of GSRS-03 (acid regurgitation), GSRS-07
(abdominal distension), and GSRS-10 (constipation) scores
were significantly higher in the RKT group than in the
PL group.
The differences in clinical characteristics between the RKT
responsive group and RKT nonresponsive group
Background factors of RKT responsive group and RKT
nonresponsive group were shown in Table 4. Presence of
concomitant systemic diseases (hypertension, insomnia,
hyperlipidemia and constipation) was the potential pre-
dictor of poor response to RKT.
Discussion
In this population of elderly PPI-refractory NERD pa-
tients with ARD, RKT combined with a standard-dose of
RPZ significantly improved the total and ARD scores
but not RS score of FSSG after an 8-week treatment.
Our results suggest that for the improvement of post-
prandial dyspeptic symptoms in elderly patients with
PPI-refractory NERD, RKT is particularly effective. Fur-
thermore, RKT was more effective in patients without
concomitant systemic diseases.
Kindt et al. have reported a relationship between symp-
tom pattern and gastric sensorimotor dysfunction in
Figure 1 Patients enrolled in this study. Of 242 patients with a clinical diagnosis of PPI-refractory NERD, 95 were elderly patients (≥65 years)
with ARD. ARD, acid-related dysmotility symptom; RKT group: rikkunshito (7.5 g/day 3 times) + rabeprazole (10 mg/day), PL group: placebo
(7.5 g/day 3 times) + rabeprazole (10 mg/day).
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tric emptying was correlated with scores for heartburn/
regurgitation, nausea/vomiting, fullness/satiety, bloating,
and lower abdominal pain. However, discomfort volume
during gastric distension was correlated with scores forTable 2 Patients background factors in the 2 groups
RKT group PL group P value
Mean age, years (range) 72.1 (65–85) 73.4 (65–83) 0.225a
Gender, n, (M/F) 17/35 8/35 0.370b
BMI (mean ± SD) 23.0 ± 3.6 22.9 ± 3.0 0.940a
Current alcohol use, n (%) 7 (13.5) 3 (7.0) 0.517b
Current smoking, n (%) 6 (11.5) 1 (2.3) 0.024b
Helicobacter pylori infection, n (%) 13 (43.3) 5 (16.7) 0.115b
Gastric mucosal atrophy, n (%) 37 (71.2) 27 (64.3) 0.096b
Redness of gastric mucosa, n (%) 10 (19.2) 3 (7.1) 0.167b
Impaired GEFV (grade III, IV), n (%) 16 (30.8) 9 (20.9) 0.427b
Esophageal hiatal hernia (grade
B and A), n (%)
23 (48.6) 17 (39.7) 0.413b
Concomitant systemic diseases,
n (%), (with)
34 (65.4) 26 (61.9) 0.785b
Total FSSG score (mean ± SD) 16.0 ± 7.0 15.1 ± 6.4 0.457c
Overall GSRS score (mean ± SD) 2.5 ± 0.9 2.3 ± 0.8 0.652c
BMI, body mass index; GEFV, gastroesophageal flap valve; FSSG, Frequency
Scale for the Symptoms of GERD; GSRS, Gastrointestinal Symptom
Rating Scale.
a, t-test; b, Fisher’s exact test; c, Wilcoxon’s signed rank test.fullness/satiety, bloating, heartburn/regurgitation, and
upper abdominal pain. In the present study, clinical char-
acteristics of elderly patients with PPI-refractory NERD
who responded to RKT were assessed by improvement
degrees of 12 subscale scores of FSSG and 15 GSRS items
after the 8-week treatment. Combination therapy with
RKT for 8 weeks showed significant improvement in 3
subscale scores (abdominal bloating, heavy feeling in
stomach after meals, and sick feeling after meals) of the
ARD domain and 1 subscale score (heartburn after meals)
of the RS domain. Transient lower esophageal sphincter
relaxations (TLESRs) are one of the major mechanisms
for reflux in GERD. Delayed gastric emptying and im-
paired gastric accommodation may trigger TLESRs. RKT
acts as a prokinetic agent that ameliorates gastric empty-
ing [13] and gastric accommodation [14]. The increase of
gastric motor activity by RKT may contribute to improve
postprandial GERD symptoms in elderly patients with
PPI-refractory NERD.
Of the 15 GSRS items, improvement degrees of GSRS-
10 (constipation) scores were significantly higher in the
RKT group than in the PL group. It is known that volun-
tary suppression of defecation delays gastric emptying in
healthy subjects [22]. The improvement that RKT has
on constipation may also be because of its prokinetic ef-
fect. A previous clinical study of 340 Japanese patients
with GERD reported that elderly patients with GERD
frequently demonstrated typical GERD symptoms at the
Figure 2 Changes in FSSG scores after treatments of RKT or placebo. (A) Changes in total, ARD and RS scores of FSSG after the 4- and
8-week treatment. (B) Improvement degrees of total, ARD and RS scores of FSSG after the 4- and 8-week treatment. Values are expressed as
mean ± SD. **P < 0.01 vs. before treatment (Wilcoxon’s signed rank test). #P < 0.05, ##P < 0.01 significant difference between each paired group
(Wilcoxon’s signed rank test).
Figure 3 Improvement degrees of 12 subscale scores of FSSG after the 8-week treatment in the RKT and placebo 2 groups.
(A) Improvement degrees in 5 subscale scores of ARD after the 8-week treatment. (B) Improvement degrees in 7 subscale scores of RS after
the 8-week treatment. Values were expressed as mean ± SD. #P < 0.05, ##P < 0.01 significant difference between each paired group (Wilcoxon’s
signed rank test).
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Table 3 Improvement degrees of GSRS after 8-week treatments of RKT or placebo
RKT group PL group P Subscale domain
(Questions)
GSRS01 (abdominal pain) 0.5 ± 1.4 0.7 ± 1.7 0.425 Abdominal pain
GSRS02 (heartburn) 1.4 ± 1.4 0.8 ± 1.8 0.240 Reflux syndrome
GSRS03 (acid regurgitation) 1.4 ± 1.9* 0.6 ± 1.6 0.038 Reflux syndrome
GSRS04 (hunger pains) 0.6 ± 1.2 0.6 ± 1.4 0.785 Abdominal pain
GSRS05 (nausea) 0.8 ± 1.6 0.1 ± 1.5 0.062 Abdominal pain
GSRS06 (borborygmus) 0.6 ± 1.4 0.5 ± 1.4 0.944 Indigestion syndrome
GSRS07 (abdominal distension) 1.0 ± 2.0* 0.2 ± 1.8 0.038 Indigestion syndrome
GSRS08 (eructation) 1.0 ± 1.4 0.3 ± 1.9 0.197 Indigestion syndrome
GSRS09 (increased flatus) 0.8 ± 1.4 0.6 ± 1.8 0.524 Indigestion syndrome
GSRS10 (constipation) 0.8 ± 1.6* 0.2 ± 1.4 0.034 Constipation syndrome
GSRS11 (diarrhea) 0.5 ± 1.5 0.6 ± 1.4 0.661 Diarrhea syndrome
GSRS12 (loose stools) 0.3 ± 1.5 0.6 ± 1.5 0.260 Diarrhea syndrome
GSRS13 (hard stools) 0.6 ± 1.5 0.4 ± 1.5 0.479 Constipation syndrome
GSRS14 (urgent need for defecation) 0.6 ± 1.4 0.4 ± 1.5 0.339 Diarrhea syndrome
GSRS15 (feeling of incomplete evacuation) 0.5 ± 1.4 0.4 ± 1.5 0.518 Constipation syndrome
(Subscale score)
Abdominal pain 0.6 ± 1.0 0.5 ± 1.3 0.538
Reflux syndrome 1.4 ± 1.5 0.7 ± 1.6 0.064
Indigestion syndrome 0.8 ± 1.2 0.4 ± 1.4 0.211
Constipation syndrome 0.6 ± 1.2 0.3 ± 1.3 0.094
Diarrhea syndrome 0.5 ± 1.3 0.5 ± 1.3 0.677
Overall score 0.8 ± 0.9 0.5 ± 1.1 0.113
GSRS, Gastrointestinal Symptom Rating Scale; the 15 GSRS items are divided into the following 5 scales: abdominal pain (abdominal pain, hunger pain, and
nausea), reflux syndrome (heartburn and acid regurgitation), diarrhea syndrome (diarrhea, loose stools, and urgent need for defecation), indigestion syndrome
(borborygmus, abdominal distension, eructation, and increased flatus), and constipation syndrome (constipation, hard stools, and a feeling of incomplete
evacuation). Values were expressed as mean ± SD. *P < 0.05, significant difference between each paired group (Wilcoxon’s signed rank test).
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the esophageal mucosal breaks presence [11]. Because
RKT was particularly effective for resolving postprandial
GERD symptoms in the present study, it may be suitable
for treatment of elderly patients with GERD.
Recently, esophageal impedance pH monitoring re-
vealed that bile reflux to the esophagus may be another
important factor in the pathogenesis of mucosal hyper-
sensitivity leading to PPI-refractory GERD. Araki et al.
showed that RKT can potently absorb bile salts [23]. In
addition, RKT improved acid regurgitation-associated
signs through prevention of both decreases in the tight
junction protein and increases in the intercellular space
of the epithelial mucosa in a rat reflux esophagitis model
[24]. These findings suggest that RKT may improve
hypersensitivity against gastric acid or bile reflux to the
esophagus. These mechanisms, which are unrelated to
motor function, could explain the effect of RKT on re-
lieving the symptoms of patients with PPI-refractory
GERD, particularly in NERD. In addition to these effects,RKT enhances ghrelin secretion and reactivity of its re-
ceptor [25-27]. Ghrelin is a digestive hormone, which
displays a wide spectrum of biological functions includ-
ing appetite stimulation, GI motility, and gastric mucosal
protection [28,29]. Interestingly, it was reported that
RKT improved decreased food intake in elderly patients
with dementia [30] and aged mice [31]. Elderly patients
with GERD have complications such as dysphagia, vomit-
ing, weight loss, anemia, and anorexia [32]. Therefore,
RKT may be a possible treatment to improve QOL in eld-
erly patients with GERD/NERD.
The placebo response in functional GI diseases includ-
ing GERD/NERD, functional dyspepsia (FD), and irrit-
able bowel syndrome (IBS) is a significant confounder of
the assessment of drug efficacy in clinical trials. Though
FSSG scores significantly decreased in the PL group dur-
ing the first 4 weeks of treatment, significant changes of
the scores were not observed during 4–8 weeks. In con-
trast, FSSG scores significantly decreased in RKT group
during 4–8 weeks. Therefore, it is believed that the
Table 4 The differences in clinical characteristics between






Mean age, years (range) 71.12(65-85) 73.12(65-85) 0.441a
Gender, n, (M/F) 10/15 4/13 0.331b
BMI (mean ± SD) 23.5 ± 4.1 22.3 ± 2.3 0.497a
Current alcohol use (Y/N) 4/21 1/16 0.632b

















15.9 ± 7.4 14.6 ± 6.5 0.616a
Total GSRS score
(mean ± SD)
2.5 ± 1.0 2.3 ± 0.8 0.722a
BMI, body mass index; GEFV, gastroesophageal flap valve; FSSG, Frequency
Scale for the Symptoms of GERD; GSRS, Gastrointestinal Symptom
Rating Scale.
a, Wilcoxon’s rank sum test; b, Fisher’s exact test.
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degree between 2 groups only in the 8th week after treat-
ment. When a patient with ≥50% improvement rate of
FSSG score is defined as a placebo responder, the pla-
cebo response rates in this population of elderly PPI-
refractory NERD patients with ARD were 34.2% and
41.9% after 4 or 8 weeks of treatment, respectively (data
not shown). Previous reports showed that placebo re-
sponse rate in GERD patients was approximately 19%
[33]. This rate is lower than placebo response rate in FD
or IBS patients (approximately 40%) [34-36]. High placebo
response rate in our cohort may be related to patients
overlapping with FD and/or IBS who unfortunately have
been included. We have fully recognized the necessity for
physiological testing using multichannel intraluminal
impedance-pH monitoring to distinguish NERD patients
form FD patients. However, it is difficult to perform such
physiological testing in all clinical institutions. This point
was an unavoidable limitation in multicenter clinical trials
as well as other similar clinical trials
Conclusions
RKT is a potential medicine in improving GERD symp-
toms in elderly PPI-refractory NERD patients with ARD.
On the basis of our results, we can conclude that RKT
was particularly effective for treatment of postprandialGERD symptoms (heavy feeling in stomach after meals,
sick feeling after meals, and heartburn after meals).
Additional file
Additional file 1: Lists of the institutional review boards.
Abbreviations
ARD: Acid-related dysmotility symptom; BMI: Body mass index; FAS: Full
analysis set; FD: Functional dyspepsia; FSSG: The frequency scale for the
symptoms of GERD; GEFV: Gastroesophageal flap valve;
GERD: Gastroesophageal reflux disease; GSRS: The Gastrointestinal symptom
rating scale; IBS: Irritable bowel syndrome; NERD: Non-erosive reflux disease;
QOL: Quality of life; RE: Reflux esophageal; RKT: Rikkunshito;
RPZ: Rabeprazole; RS: Reflux symptom; PPI: Proton pump inhibitor; SMO: Site
management organization; TLESRs: Transient lower esophageal sphincter
relaxations.
Competing interests
Some authors have received research grants, respectively: Mototsugu Kato
from Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co., Ltd.,
AstraZeneca KK., Ltd., Astellas Pharma Inc., and Daiichi-Sankyo Co., Ltd.;
Hiroshi Takeda from Tsumura & Co. Ltd., Eiji Umegaki from Takeda
Pharmaceutical Co., Ltd.; Akihito Nagahara from Daiichi-Sankyo Co., Ltd.;
Katsuhiko Iwakiri from Takeda Pharmaceutical Co.; Yoshikazu Kinoshita has
served in speaking and teaching commitments for AstraZeneca KK,
Takeda Pharmaceutical Co., Ltd., Astellas Pharma Inc., Eisai Co., Ltd., Taiho
Pharmaceutical Co., Ltd., Daiichi-Sankyo, and MSD; ST from Eisai Co., Ltd.;
Sumio Watanabe from AstraZeneca Inc., Eisai Co., Ltd., and Takeda
Pharmaceutical Co., Ltd.; Kazuhide Higuchi from AstraZeneca KK, Otsuka
Pharmaceutical Co. Ltd., Eisai Co., Ltd., Daiichi-Sankyo Co. Ltd., and
Nippon-Shinyaku Co. Ltd.; Motoyasu Kusano from Eisai Co., Ltd.; Kazuma
Fujimoto from Eisai Co., Ltd., AstraZeneca KK., and Daiichi-Sankyo Co. Ltd.;
Tetsuo Arakawa from Eisai Co., Ltd., Daiichi-Sankyo Co. Ltd., and Otsuka
Pharmaceutical Co., Ltd. The Center for Clinical Research at Hamamatsu
University School of Medicine has received grants from Takeda
Pharmaceutical Co., Ltd., AstraZeneca KK, Eisai Co., Ltd., and Daiichi-Sankyo
Co. Ltd., and Takahisa Furuta has received lecture fees from those
companies. The Division of Upper Gastroenterology, Department of
Internal Medicine at Hyogo College of Medicine has received grants from
AstraZeneca KK, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd.,
Eisai Co., Ltd., Tsumura & Co. Ltd., Dainippon Sumitomo Pharma Co. Ltd.,
Yakult Co. Ltd., and Takeda Pharmaceutical Co., Ltd. The following people
have nothing to declare: Yasuhisa Sakata, Kazunari Tominaga, Yasuyuki
Shimoyama, Ryuichi Iwakiri, Kenji Furuta, Koichi Sakurai, Takeo Odaka,
Hiroaki Kusunoki, Kazunari Murakami, and Ken Haruma.
Financial support for this study was provided by the Waksman Foundation
of Japan INC.
Authors’ contributions
Contributions to study concept and design, interpretation of data, drafting of
the manuscript, critical revision of the manuscript for important intellectual
content: KT, MK, HT, YS, EU, RI, YK, KH, KH, MK, KF, and TA. Contributions to
drafting of the manuscript and critical revision of the manuscript for
important intellectual content: YS, KF, KS, TO, HK, AN, and KI. Contributions to
critical revision of the manuscript for important intellectual content: TF, KM,
and HM. Contributions to study concept and design, interpretation of data,
critical revision of the manuscript for important intellectual content: KH, ST,
and SW. All authors approved the final version of the manuscript.
Acknowledgements
We thank the site investigators for their participation and Sogo Rinsho
Holdings Co., Ltd, Tokyo, Japan in the present study. We are grateful to the
G-PRIDE study group as described below for contribution of to this study.
The G-PRIDE study group: Katsuhiro Mabe, Hokkaido University Hospital;
Mineo Kudo, Sapporo Hokuyu Hospital; Hiroko Oizumi, Hokuyukai Kaisei
Hospital; Kazunori Eto, Shuichi Muto, Tomakomai City Hospital; Shinya
Serikawa, Jyun Sakamoto, Sapporo Higashi Tokushukai Hospital; Kaku Hokari,
Keiyukai Sapporo Hospital; Hiroaki Nema, Nikko Memorial Hospital; Satoru
Sakata et al. BMC Gastroenterology 2014, 14:116 Page 9 of 10
http://www.biomedcentral.com/1471-230X/14/116Kakizaki, Gunma University Hospital; Tomohiro Kudo, Takasaki General
Medical Center, Hideyuki Suzuki, Kazuhiro Takahashi, Haramachi Red Cross
Hospital; Daisuke Asaoka, Mariko Hojyo, Jyuntendo University School of
Medicine; Kenji Nakamura, Kengo Tokunaga, Kyorin University School of
Medicine; Tomoaki Matsumura, Chiba University Graduate School of
Medicine; Kenichi Nakajima, Tako Central Hospital; Mitsushige Sugimoto,
Takanori Yamada, Hamamatsu University School of Medicine; Yasuhiko
Maruyama, Masanobu Kageoka, Fujieda Municipal General Hospital; Naohito
Shirai, Enshu Hospital; Makoto Kodaira, Yaizu City General Hospital; Testuya
Tanigawa, Osaka City University Guraduate School of Medicine; Natsuhiko
Kameda, Hironori Uno, Ohno Memorial Hospital; Koichiro Nakagawa,
Higashisumiyoshi Morimoto Hospital; Masahiro Ochi, Meijibashi Hospital;
Kenjiro Otani, Ryuta Oiso, Nagayoshi General Hospital; Kiyoshi Ashida, Hirosi
Yamashita, Osaka Saiseikai Nakatsu Hospital; Masahiro Sakaguchi, Moriguchi
Keijinkai Hospital; Sanomura Makoto, Shinya Kaseda, Hokusetsu General
Hopital, Seikeikai Hospital; Masahiro Shiraki, Shinsei Hospital; Osamu Saito,
Rapport Aoyama Second Hospital; Takashi Kondo, Toshihiko Tomita, Jiro
Watari, Hirokazu Fukui; Hyogo College of Medicine; Takashi Abe, Jyunsuke
Oku, Takarazuka City Hospital; Mitsuhiko Kawaguchi, Kawaguchi Medical
Clinic; Kyoichi Adachi, Shimane University Faculty of Medicine; Yoshinori
Komazawa, Mika Yuki, Izumo City General Medical Center; Tomoo Fujisawa,
Yoshinori Kushiyama, Erina Kakuta, Matsue Red Cross Hospital; Youichi
Miyaoka, Yoshiya Morito, Shimane Prefectural Central Hospital; Koichiro
Furuta, Masuda Medical Association Hospital; Yuichiro Eguchi, Shigetaka
Kuroki, Eguchi Hospital; Seiji Tsunada, Ureshino Medical Center; Shinichi
Ogata, Saga Prefectural Hospital Koseikan; Kohei Yamanouchi, Imari Arita
Kyoritsu Hospital; Takahiro Noda, Nanae Tsuruoka, Karatsu Red Cross
Hospital; Kiwamu Hasuda, Hattori Gastrointestinal Clinic; Yasushi Oda, Oda
Gastrointestinal Clinic; Testuya Murao, Kumamoto Medical Center; Seiji Shiota,
Oita University Faculty of Medicine; Hisanori Abe, Arita Gastrointestinal
Hospital; Shigeaki Yasaka, Health Insurance Nankai Hospital; Fuminao
Takeshima, Nagasaki University Graduate School of Biomedical Sciences.
Author details
1Department of Internal Medicine and Gastroenterology, Saga Medical
School, 5-1-1 Nabeshima, Saga 849-8501, Japan. 2Department of
Gastroenterology, Osaka City University Graduate School of Medicine, Osaka
City, Japan. 3Division of Endoscopy, Hokkaido University Hospital, Hokkaido,
Japan. 4Department of Pathophysiology and Therapeutics, Hokkaido
University Faculty of Pharmaceutical Sciences, Hokkaido, Japan. 5Department
of Endoscopy and Endoscopic Surgery, Gunma University Hospital, Gunma,
Japan. 6Second Department of Internal Medicine, Osaka Medical College,
Osaka, Japan. 7Department of Internal Medicine and Gastrointestinal
Endoscopy, Saga Medical School, Saga, Japan. 8Department of
Gastroenterology and Hepatology, Shimane University School of Medicine,
Shimane, Japan. 9Department of Gastroenterology, Kumamoto University
Graduate School of Medicine, Kumamoto, Japan. 10Department of
Gastroenterology, Chiba University Graduate School of Medicine, Chiba,
Japan. 11Department of Gastroenterology, Kawasaki Medical School,
Kawasaki, Japan. 12Department of Gastroenterology, Juntendo University
School of Medicine, Juntendo, Japan. 13Department of Internal Medicine,
Nippon Medical School Chiba Hokusoh Hospital, Nippon, Japan. 14Center for
Clinical Research, Hamamatsu University School of Medicine, Hamamatsu,
Japan. 15Department of Gastroenterology, Faculty of Medicine, Oita
University, Oita, Japan. 16Division of Upper Gastroenterology, Department of
Internal Medicine, Hyogo College of Medicine, Hyogo, Japan. 17Third
Department of Internal Medicine, Kyorin Medical College, Kyorin, Japan.
Received: 3 April 2014 Accepted: 26 June 2014
Published: 2 July 2014References
1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group:
The Montreal definition and classification of gastroesophageal reflux
disease: a global evidence based consensus. Am J Gastroenterol 2006,
101:1900–1920.
2. Coté GA, Howden CW: Potential adverse effects of proton pump
inhibitors. Curr Gastroenterol Rep 2008, 10:208–214.
3. Fass R: Proton-pump inhibitor therapy in patients with gastro-oesophageal
reflux disease: putative mechanisms of failure. Drugs 2007, 67:1521–1530.4. Fass R, Shapiro M, Dekel R, Sewell J: Systematic review: proton pump
inhibitor failure in gastro-oesophageal reflux disease. Where next?
Aliment Pharmacol Ther 2005, 22:79–94.
5. Fujimoto K: Review article: prevalence and epidemiology of gastro-oesophageal
reflux disease in Japan. Aliment Pharmacol Ther 2004, 20(Suppl 8):5–8.
6. Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K: Strategy for
treatment of nonerosive reflux disease in Asia. World J Gastroenterol 2008,
14:3123–3128.
7. Bacak BS, Patel M, Tweed E, Danis P: What is the best way to manage
GERD symptoms in the elderly? J Fam Pract 2006, 55:251–254. 258.
8. Fujimoto K, Iwakiri R, Okamoto K, Oda K, Tanaka A, Tsunada S, Sakata H, Kikkawa
A, Shimoda R, Matsunaga K, Watanabe K, Wu B, Nakahara S, Ootani H, Ootani A:
Characteristics of gastroesophageal reflux disease in Japan: increased
prevalence in elderly women. J Gastroenterol 2003, 38(Suppl 15):3–6.
9. Fujimoto K, Hongo M: Risk factors for relapse of erosive GERD during
long-term maintenance treatment with proton pump inhibitor:
a prospective multicenter study in Japan. J Gastroenterol 2010,
45:1193–1200.
10. Furuta T, Shimatani T, Sugimoto M, Ishihara S, Fujiwara Y, Kusano M, Koike T,
Hongo M, Chiba T, Kinoshita Y, Acid-Related Symptom Research Group:
Investigation of pretreatment prediction of proton pump inhibitor
(PPI)-resistant patients with gastroesophageal reflux disease and the
dose escalation challenge of PPIs-TORNADO study: a multicenter
prospective study by the Acid-Related Symptom Research Group in
Japan. J Gastroenterol 2011, 46:1273–1283.
11. Furuta K, Kushiyama Y, Kawashima K, Shibagaki K, Komazawa Y, Fujishiro H,
Kitajima N, Adachi K, Kinoshita Y: Comparisons of symptoms reported by
elderly and non-elderly patients with GERD. J Gastroenterol 2012, 47:144–149.
12. Tominaga K, Arakawa T: Kampo medicines for gastrointestinal tract
disorders: a review of basic science and clinical evidence and their
future application. J Gastroenterol 2013, 48:452–462.
13. Tatsuta M, Iishi H: Effect of treatment with liu-jun-zi-tang (TJ-43) on
gastric emptying and gastrointestinal symptoms in dyspeptic patients.
Aliment Pharmacol Ther 1993, 7:459–462.
14. Kusunoki H, Haruma K, Hata J, Ishii M, Kamada T, Yamashita N, Honda K,
Inoue K, Imamura H, Manabe N, Shiotani A, Tsunoda T: Efficacy of
Rikkunshito, a traditional Japanese medicine (Kampo), in treating
functional dyspepsia. Intern Med 2010, 49:2195–2202.
15. Tominaga K, Iwakiri R, Fujimoto K, Fujiwara Y, Tanaka M, Shimoyama Y,
Umegaki E, Higuchi K, Kusano M, Arakawa T, GERD 4 Study Group:
Rikkunshito improves symptoms in PPI-refractory GERD patients: a pro-
spective, randomized, multicenter trial in Japan. J Gastroenterol 2012,
47:284–292.
16. Tominaga K, Kato M, Takeda H, Shimoyama Y, Umegaki E, Iwakiri R, Furuta K,
Sakurai K, Odaka T, Kusunoki H, Nagahara A, Iwakiri K, Furuta T, Murakami K,
Miwa H, Kinoshita Y, Haruma K, Takahashi S, Watanabe S, Higuchi K, Kusano M,
Fujimoto K, Arakawa T, G-PRIDE Study Group: A randomized, placebo-controlled,
double-blind clinical trial of rikkunshito for patients with non-erosive reflux
disease refractory to proton-pump inhibitor: the G-PRIDE study. J Gastroenterol
2014, in press.
17. Tominaga K, Kido T, Ochi M, Sadakane C, Mase A, Okazaki H, Yamagami H,
Tanigawa T, Watanabe K, Watanabe T, Fujiwara Y, Oshitani N, Arakawa T:
The traditional Japanese medicine rikkunshito promotes gastric
emptying via the antagonistic action of the 5-HT3 receptor pathway
in rats. Evid Based Complement Alternat Med 2011, 2011:248481.
doi:10.1093/ecam/nep173.
18. Fass R: Symptom assessment tools for gastroesophageal reflux disease
(GERD) treatment. J Clin Gastroenterol 2007, 41:437–444.
19. Kusano M, Shimoyama Y, Sugimoto S, Kawamura O, Maeda M, Minashi K,
Kuribayashi S, Higuchi T, Zai H, Ino K, Horikoshi T, Sugiyama T, Toki M,
Ohwada T, Mori M: Development and evaluation of FSSG; frequency scale
for the symptoms of GERD. J Gastroenterol 2004, 39:888–891.
20. Revicki DA, Wood M, Wiklund I, Crawley J: Reliability and validity of the
gastrointestinal symptom rating scale in patients with gastroesophageal
reflux disease. Qual Life Res 1998, 7:75–83.
21. Kindt S, Dubois D, Van Oudenhove L, Caenepeel P, Arts J, Bisschops R, Tack J:
Relationship between symptom pattern, assessed by the PAGI-SYM
questionnaire, and gastric sensorimotor dysfunction in functional
dyspepsia. Neurogastroenterol Motil 2009, 21:1183. e105.
22. Tieerdsma HC, Smout AJ, Akkermans LM: Voluntary suppression of
defecation delays gastric emptying. Dig Dis Sci 1993, 38:832–836.
Sakata et al. BMC Gastroenterology 2014, 14:116 Page 10 of 10
http://www.biomedcentral.com/1471-230X/14/11623. Araki Y, Mukaisho KI, Fujiyama Y, Hattori T, Sugihara H: The herbal medicine
rikkunshito exhibits strong and differential adsorption properties for bile
salts. Exp Ther Med 2012, 3:645–649.
24. Miwa H, Koseki J, Oshima T, Kondo T, Tomita T, Watari J, Matsumoto T,
Hattori T, Kubota K, Iizuka S: Rikkunshito, a traditional Japanese medicine,
may relieve abdominal symptoms in rats with experimental esophagitis
by improving the barrier function of epithelial cells in esophageal
mucosa. J Gastroenterol 2010, 45:478–487.
25. Takeda H, Sadakane C, Hattori T, Katsurada T, Ohkawara T, Nagai K, Asaka M:
Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in
rats via 5-HT2 receptor antagonism. Gastroenterology 2008, 134:2004–2013.
26. Matsumura T, Arai M, Yonemitsu Y, Maruoka D, Tanaka T, Suzuki T,
Yoshikawa M, Imazeki F, Yokosuka O: The traditional Japanese medicine
Rikkunshito increases the plasma level of ghrelin in humans and mice.
J Gastroenterol 2010, 45:300–307.
27. Fujitsuka N, Asakawa A, Uezono Y, Minami K, Yamaguchi T, Niijima A,
Yada T, Maejima Y, Sedbazar U, Sakai T: Potentiation of ghrelin signaling
attenuates cancer anorexia-cachexia and prolongs survival. Transl Psychiatr
2011, 26:e23.
28. van der Lely AJ, Tschop M, Heiman ML, Ghigo E: Biological, physiological,
pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev
2004, 25:426–457.
29. Konturek PC, Brzozowski T, Pajdo R, Nikiforuk A, Kwiecien S, Harsch I,
Drozdowicz D, Hahn EG, Konturek SJ: Ghrelin-a new gastroprotective
factor in gastric mucosa. J Physiol Pharmacol 2004, 55:325–336.
30. Utumi Y, Iseki E, Murayama N, Nozawa M, Kumagai R, Matsubara Y, Ichimiya Y,
Arai H: Effect of Rikkunshi-to on appetite loss found in elderly dementia
patients: a preliminary study. Psychogeriatrics 2011, 11:34–39.
31. Takeda H, Muto S, Hattori T, Sadakane C, Tsuchiya K, Katsurada T, Ohkawara T,
Oridate N, Asaka M: Rikkunshito ameliorates the aging-associated decrease
in ghrelin receptor reactivity via phosphodiesterase III inhibition.
Endocrinology 2010, 151:244–252.
32. Pilotto A, Franceschi M, Paris F: Recent advances in the treatment of GERD
in the elderly: focus on proton pump inhibitors. Int J Clin Pract 2005,
59:1204–1209.
33. Cremonini F, Ziogas DC, Chang HY, Kokkotou E, Kelley JM, Conboy L,
Kaptchuk TJ, Lembo AJ: Meta-analysis: the effects of placebo treatment
on gastrooesophageal reflux disease. Aliment Pharmacol Ther 2010,
32:29–42.
34. Hongo M: Epidemiology of FGID symptoms in Japanese general
population with reference to life style. J Gastroenterol Hepatol 2011,
26(Suppl 3):19–22.
35. Tack J, Fried M, Houghton LA, Spicak J, Fisher G: Systematic review: the
efficacy of treatments for irritable bowel syndrome–a European
perspective. Aliment Pharmacol Ther 2006, 24:183–205.
36. Talley NJ, Locke GR, Lahr BD, Zinsmeister AR, Cohard-Radice M, D'Elia TV,
Tack J, Earnest DL: Predictors of the placebo response in functional
dyspepsia. Aliment Pharmacol Ther 2006, 23:923–936.
doi:10.1186/1471-230X-14-116
Cite this article as: Sakata et al.: Clinical characteristics of elderly
patients with proton pump inhibitor-refractory non-erosive reflux
disease from the G-PRIDE study who responded to rikkunshito.
BMC Gastroenterology 2014 14:116.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
